Rob Seitz’s 25+ years of experience includes roles as chief executive officer, chief biotechnology officer, head of data science, and over five years of consulting. Commercial products that he has developed include:

• DetermaIO for identifying patients with increased efficacy when treated with immune checkpoint inhibitors.

• Mammostrat for identifying ER+ breast cancer patients treated with anti-hormonal therapy who have similar outcomes to those patients who have been treated with both anti-hormonal therapy and chemotherapy.

• TLE3 which identifies increased efficacy among patients treated with taxanes.

Mr. Seitz is the author of dozens of peer reviewed publications in the biomarker space, and the holder of 13 patents, with several more pending.

Brief Work History
Mr. Seitz served as a CEO (Applied Genomics which sold to Clarient in 2009), Senior Vice President (Clarient, Inc., a GE company), Chief Biotechnology Officer and interim CEO (Insight Genetics), Head of Immune Oncology (Oncocyte, Inc), and as a partner with the Bethesda Group Consultants. He has a B.S. degree in Chemistry from the University of South Alabama and an M. Div. degree from Fuller Theological Seminary.